Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials
Year: 2015
Type: article
Abstract: INTRODUCTION: Practice effects are characteristic of nearly all standard cognitive tasks when repeated during serial assessments and are frequently important confounders in clinical trials. METHODS: We summarize evidence that gains in neuropsychological test performance scores associated with practice effects occur as artifactual changes associated with serial testing within clinical trials. We identify and emphasize such gains in older, non-cognitively impaired individuals and estimate an effect size of 0.25 for composite cognitive measures in older populations assessed three times in a 6- to 12-month period. RESULTS: We identified three complementary approaches that can be used to attenuate practice effects: (1) massed practice in a prebaseline period to reduce task familiarity effects; (2) tests designed to reduce practice-related gains so that item-specific driven improvements are minimized by using tasks that minimize strategy and/or maximize interitem interference; and (3) well-matched alternate forms. DISCUSSION: We have drawn attention to and increased awareness of practice effect-related gains that could result in type 1 or type 2 errors in trials. Successfully managing practice effects will eliminate a large source of error and reduce the likelihood of misinterpretation of clinical trials outcomes.
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,540
Awards: LONGITUDINAL STUDY OF A NOVEL PERFORMANCE-BASED MEASURE OF DAILY FUNCTION, G3042542331, Estrogen Receptor-beta phytoSERMs for Management of Menopause and Memory Decline, G4119534169, G453222670, G5324093878, G5850682332, Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and Improve, Alzheimer Disease Research Center, BDNF val66met Genotype and Age: Impact on Biomarkers and Exercise-based Treatment, Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I, G982116513
OpenAlex ID: W2079020664
